Immune landscape of pancreatic cancer development and drug resistance explores the advances in immune-based therapies aimed at harnessing the power of the immune system against pancreatic cancer and rewiring tumor microenvironments to eradicate pancreatic cells. With a strong focus on the development of therapeutic methods to improve the survival rates of pancreatic cancer, this book also shows the latest trends in immune targeted approaches for pancreatic cancer treatment.
In 12 chapters Immune landscape of pancreatic cancer development and drug resistance discusses the current understanding of PC development and its various mutational and immune features and explore some of the new immune-based therapies aimed at targeting pancreatic cancer. It covers the urgent need for developing novel therapeutic modalities and aims at delineating future fields and avenues of research in pancreatic cancer treatment. The book provides the reader with an updated understanding of the immune landscape of PC and an all-encompassing overview of the latest trends in immune targeted approaches for PC treatment. This book is a valuable resource for health professionals, scientists and researchers, students, and all those who wish to broaden their knowledge of the advances in immunotherapy in pancreatic cancer.
- Summarizes the potential combination strategies and latest clinical trials in pancreatic cancer
- Provides an in-depth overview of our current understanding of pancreatic cancer development, including its mutational and immune features
- Explores some of the new immune-based therapies aimed at targeting PC
- Shows pancreatic cancer progression and basic elements in tumor microenvironments and their role in PC progression, also covering immunotherapy strategies
Sprache
Verlagsort
Verlagsgruppe
Elsevier Science & Techn.
Dateigröße
ISBN-13
978-0-443-23522-1 (9780443235221)
Schweitzer Klassifikation
1. Introduction2. Molecular profiling and mutational landscape of pancreatic cancer3. Tumor microenvironment and immune components interaction in pancreatic ductal adenocarcinoma4. Identification of immune targeted molecules in pancreatic ductal adenocarcinoma5. Targeting macrophages for pancreatic cancer therapy6. Targeting cancer-associated fibroblasts in pancreatic ductal adenocarcinoma7. Targeting short-lived immunosuppressive myeloid cells for PDAC therapy8. Targeting T-regs in PDAC9. Immune-modulators for PDAC therapy10. Current clinical trials in PDAC immunotherapy11. Precision medicine in PDAC immunotherapy12. Artificial intelligence in pancreatic cancer immunotherapy
